Trial · NCT00811018
Results by group72
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 72
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Sitaxsentan | AEs | 1150 | participants | |
| Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Sitaxsentan | SAEs | 586 | participants | |
| The Percentage of Participants Who Experience an Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Value Greater Than (>) 3.0 Times (x) the Upper Limit of Normal Range (ULN) | Sitaxsentan | > 3 x ULN and less than or equal to (<=) 5x ULN | 5.12 | percentage of participants | |
| The Percentage of Participants Who Experience an Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Value Greater Than (>) 3.0 Times (x) the Upper Limit of Normal Range (ULN) | Sitaxsentan | > 5 x ULN and <= 8 x ULN | 4.45 | percentage of participants | |
| The Percentage of Participants Who Experience an Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Value Greater Than (>) 3.0 Times (x) the Upper Limit of Normal Range (ULN) | Sitaxsentan | > 8 x ULN and <= 10 x ULN | 0.76 | percentage of participants | |
| The Percentage of Participants Who Experience an Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) Value Greater Than (>) 3.0 Times (x) the Upper Limit of Normal Range (ULN) | Sitaxsentan | > 10 x ULN | 2.60 | percentage of participants | |
| The Percentage of Participants Who Experience an ALT and AST Value > 3.0 x ULN | Sitaxsentan | > 3 x ULN and <= 5 x ULN | 3.94 | percentage of participants | |
| The Percentage of Participants Who Experience an ALT and AST Value > 3.0 x ULN | Sitaxsentan | > 5 x ULN and <= 8 x ULN | 2.60 | percentage of participants | |
| The Percentage of Participants Who Experience an ALT and AST Value > 3.0 x ULN | Sitaxsentan | > 8 x ULN and <= 10 x ULN | 0.67 | percentage of participants | |
| The Percentage of Participants Who Experience an ALT and AST Value > 3.0 x ULN | Sitaxsentan | > 10 x ULN | 1.26 | percentage of participants | |
| Percentage of Participants With Total Bilirubin > 1.5 x ULN | Sitaxsentan | >= 1.5 x ULN and <2 x ULN | 10.23 | percentage of participants | |
| Percentage of Participants With Total Bilirubin > 1.5 x ULN | Sitaxsentan | >= 2 x ULN and < 3x ULN | 6.80 | percentage of participants | |
| Percentage of Participants With Total Bilirubin > 1.5 x ULN | Sitaxsentan | >= 3x ULN | 5.03 | percentage of participants | |
| Percentage of Participants With Laboratory Test Abnormalities (Hematology) | Sitaxsentan | Basophiles (n=814) | 4.1 | percentage of participants | |
| Percentage of Participants With Laboratory Test Abnormalities (Hematology) | Sitaxsentan | Eosinophiles % (n=3) | 100 | percentage of participants | |
| Percentage of Participants With Laboratory Test Abnormalities (Hematology) | Sitaxsentan | Eosinophils (n=785) | 20.6 | percentage of participants | |
| Percentage of Participants With Laboratory Test Abnormalities (Hematology) | Sitaxsentan | Hematocrit (n=537) | 46.2 | percentage of participants | |
| Percentage of Participants With Laboratory Test Abnormalities (Hematology) | Sitaxsentan | Hemoglobin (n=573) | 48.7 | percentage of participants | |
| Percentage of Participants With Laboratory Test Abnormalities (Hematology) | Sitaxsentan | Lymphocytes (n=737) | 35.5 | percentage of participants | |
| Percentage of Participants With Laboratory Test Abnormalities (Hematology) | Sitaxsentan | Mean Corpuscular Hemoglobin (n=56) | 21.4 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00811018/results